CA2997376C - Methods of treating neurodegenerative disorders in a particular patient population - Google Patents

Methods of treating neurodegenerative disorders in a particular patient population Download PDF

Info

Publication number
CA2997376C
CA2997376C CA2997376A CA2997376A CA2997376C CA 2997376 C CA2997376 C CA 2997376C CA 2997376 A CA2997376 A CA 2997376A CA 2997376 A CA2997376 A CA 2997376A CA 2997376 C CA2997376 C CA 2997376C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
subject
apoe4
mmse
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2997376A
Other languages
English (en)
French (fr)
Other versions
CA2997376A1 (en
Inventor
Susan ABUSHAKRA
Aidan POWER
Martin TOLAR
John Hey
Jeremy Yu
Petr Kocis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzheon Inc
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2997376(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of CA2997376A1 publication Critical patent/CA2997376A1/en
Application granted granted Critical
Publication of CA2997376C publication Critical patent/CA2997376C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2997376A 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population Active CA2997376C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (2)

Publication Number Publication Date
CA2997376A1 CA2997376A1 (en) 2017-03-16
CA2997376C true CA2997376C (en) 2024-05-14

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997376A Active CA2997376C (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP4275750A3 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102412997B1 (enExample)
CN (3) CN108289870A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015230972B2 (en) 2014-03-21 2021-05-27 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
PL3829568T3 (pl) * 2018-08-01 2024-03-25 Alzheon, Inc. Pochodne kwasu sulfopropanowego do leczenia zaburzeń neurodegeneracyjnych
LT3829563T (lt) * 2018-08-01 2025-02-25 Alzheon, Inc. 3-sulfopropano rūgštis neurodegeneracinėms ligoms gydyti
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CN114269949A (zh) 2019-06-17 2022-04-01 阿尔泽恩股份有限公司 用于治疗神经变性病症的方法
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.
US20250127734A1 (en) * 2022-02-07 2025-04-24 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1994009155A1 (en) 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
WO2005060393A2 (en) 2003-08-11 2005-07-07 California Institute Of Technology Microfluidic large scale integration
JP2008535907A (ja) * 2005-04-12 2008-09-04 ニユーロケム（インターナショナル）、リミテッド アミロイド阻害化合物の薬学的製剤
EP2862581B1 (en) 2006-10-12 2021-08-11 BHI Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US20100183513A1 (en) 2006-11-24 2010-07-22 Wolfgang Froestl N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
DK2605655T3 (en) * 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
JP6424210B2 (ja) * 2013-05-06 2018-11-14 バクスアルタ インコーポレイテッド プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療
BR112016018170A2 (pt) 2014-02-08 2018-02-20 Genentech, Inc. métodos para tratar doença de alzheimer
AU2015230972B2 (en) 2014-03-21 2021-05-27 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population

Also Published As

Publication number Publication date
WO2017044840A1 (en) 2017-03-16
SMT202300250T1 (it) 2023-09-06
MD3347002T2 (ro) 2023-10-31
HK1257874A1 (en) 2019-11-01
MX2018003023A (es) 2018-06-06
KR20180051561A (ko) 2018-05-16
DK3347002T3 (da) 2023-08-14
US20230414541A1 (en) 2023-12-28
PL3347002T3 (pl) 2023-11-13
RS64481B1 (sr) 2023-09-29
FI3347002T3 (fi) 2023-08-10
US11191742B2 (en) 2021-12-07
CN108289870A (zh) 2018-07-17
JP2022145949A (ja) 2022-10-04
LT3347002T (lt) 2023-09-11
US20220096406A1 (en) 2022-03-31
CN116712422A (zh) 2023-09-08
MX2022003128A (es) 2022-08-02
EP3347002B1 (en) 2023-06-07
JP2025065545A (ja) 2025-04-17
AU2016319107A1 (en) 2018-03-22
KR102412997B1 (ko) 2022-06-23
KR20220042480A (ko) 2022-04-05
AU2016319107B2 (en) 2021-02-25
KR102547164B1 (ko) 2023-06-22
EP4275750A3 (en) 2024-01-17
JP2018526407A (ja) 2018-09-13
CA2997376A1 (en) 2017-03-16
JP6789579B2 (ja) 2020-11-25
HRP20230809T1 (hr) 2023-10-27
HUE062511T2 (hu) 2023-11-28
EP3347002A4 (en) 2019-04-24
PT3347002T (pt) 2023-07-27
JP2020200352A (ja) 2020-12-17
EP4275750A2 (en) 2023-11-15
SI3347002T1 (sl) 2023-12-29
EP3347002A1 (en) 2018-07-18
CN116712423A (zh) 2023-09-08
MX392677B (es) 2025-03-24
ES2952727T3 (es) 2023-11-03
JP7128536B2 (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
US20230414541A1 (en) Methods of treating neurodegenerative disorders in a particular population
ES2698927T3 (es) Terapia para trastornos neurológicos basada en baclofeno y acamprosato
EP2680836B1 (en) New compositions for treating neurological disorders
CN109890391B (zh) 痴呆症的治疗
CN107669668A (zh) 治疗多发性硬化症的组合疗法
EP3962488A1 (en) A method of treating mental, behavioral, cognitive disorders
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
US12042493B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
US10736876B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
US20210236445A1 (en) Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
HK1190607A (en) New compositions for treating neurological disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907

EEER Examination request

Effective date: 20210907